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Abstract
The increased availability of electronic health records (EHRs) have spearheaded the ini-
tiative for precision medicine using data driven approaches. Essential to this effort is the
ability to identify patients with certain medical conditions of interest from simple queries
on EHRs, or EHR-based phenotypes. Existing rule–based phenotyping approaches are
extremely labor intensive. Instead, dimensionality reduction and latent factor estimation
techniques from machine learning can be adapted for phenotype extraction with no (or
minimal) human supervision.
We propose to identify an easily interpretable latent space shared across various sources
of EHR data as potential candidates for phenotypes. By incorporating multiple EHR data
sources (e.g., diagnosis, medications, and lab reports) available in heterogeneous datatypes
in a generalized Collective Matrix Factorization (CMF), our methods can generate rich
phenotypes. Further, easy interpretability in phenotyping application requires sparse repre-
sentations of the candidate phenotypes, for example each phenotype derived from patients’
medication and diagnosis data should preferably be represented by handful of diagnosis and
medications, (5–10 active components). We propose a constrained formulation of CMF for
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estimating sparse phenotypes. We demonstrate the efficacy of our model through an ex-
tensive empirical study on EHR data from Vanderbilt University Medical Center.
Keywords: high throughput phenotyping; collective matrix factorization; non-negative
matrix factorization; sparsity constraints; combining multiple divergences.
1. Introduction
Mining electronic health records (EHRs) can drastically improve clinical care and facilitate
knowledge discovery. In particular, EHR-driven phenotyping which involves identification
of a set of clinical features or characteristic indicative of a medical condition from EHR
data has been a key focus of EHR data analyses (NIH Health Care Systems Research Col-
laboratory, 2014). Phenotypes are important for targeting patients for screening tests and
interventions, improving multisite clinical trials, and to support surveillance of infectious
diseases and rare disease complications. While existing efforts (e.g., eMerge Network, Phe-
notype KnowedgeBase, and the SHARPn program) have illustrated the promise of EHR–
driven phenotypes, state of the art phenotype development generally requires an iterative
and collaborative effort between clinicians and IT professionals to compose a series of rules
for reproducible queries of EHR databases (Hripcsak and Albers, 2013; Newton et al., 2013).
A single phenotype takes substantial time, effort, and expert knowledge to develop. Data
mining tools such as support vector machines (Carroll et al., 2011), active learning ap-
proaches (Chen et al., 2013) and inductive logic programming (Peissig et al., 2014), have
been recently used to partially automate the phenotyping process. Yet, these work require
annotated samples to obtain good performance. As such annotations are expensive and
time consuming to obtain, it is of interest to investigate unsupervised learning tools for
automated phenotyping.
Phenotyping can be viewed as a form of dimensionality reduction of EHR data, where
each phenotype or medical condition of interest represents a latent space (Hripcsak and
Albers, 2013) and the rich literature in the field of machine learning for latent space estima-
tion can be suitably adapted to automate and speed up the phenotype extraction process.
Several factors contribute to the quality of phenotypes extracted from EHR data, and it is
advantageous to consider these factors in choosing the appropriate dimensionality reduction
tools for phenotyping. A review of the top 10 phenotypes across different studies showed
that several data sources are typically used to define a phenotype (Shivade et al., 2014).
Additionally, EHR data is commonly available in heterogeneous datatypes. For example,
laboratory test results are often in the form of a real–valued number, patient demographic
information can be encoded as a binary value, and procedure codes contain the number of
times, a non-negative integer, the procedure is performed. Thus, an automated phenotyping
process that can incorporate data from heterogeneous datatypes and diverse sources can
help identify rich existing as well as novel medical concepts.
Recent work has illustrated the promise of tensor factorization to generate phenotypes
with minimal human supervision (Ho et al., 2014b; Wang et al., 2015; Henao et al., 2015)
Latent space shared by various modes of higher order tensors are easier to interpret; and
also more accurately capture the multi–source nature of phenotypes. However, rich multi–
way interactions required to form tensors is often not available in existing EHR data, for
example, in a simple 3rd order patient-diagnosis-medication tensor, the (i, j, k)th entry of the
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observation requires detailed information on the number of times patient i was prescribed
medication k in response to diagnosis j. In practice, much of the EHR data is available
in flat formats that are more readily represented as matrices rather than tensors, e.g., a
patient-diagnosis and a patient-medication matrix. Moreover, maintaining infrastructure to
record and store higher order multi–way interactions is resource–intensive as the number of
such possible interactions exponentially increase with each additional source. Alternatively,
tensors constructed by approximating higher order interactions from flat format data could
lead to noisy correlations and biased results. These motivate the exploration of tools that
directly work with multiple sources of matrix valued data.
In this paper, we propose unsupervised models for learning phenotypes from EHR data
that are available as a collection of matrices. Collective Matrix Factorization (CMF) (Singh
and Gordon, 2008) is an effective tool for identifying a latent space shared across multiple
sources of data. In CMF, a collection of related matrices are jointly factorized into low–
rank factors that are shared across the entire collection. For the phenotyping application,
we introduce various structural and methodological modifications to the basic CMF model
towards enhancing interpretability of candidate phenotypes.
• Heterogeneous datatypes: Each source of EHR data can contain diverse datatype
representations, such as numeric, count, or integer elements. Thus, it is desirable to use
loss functions that are appropriate for the data in each source. We observe that a class
of divergences called the Bregman divergences are appropriate for our application as this
class includes divergence functions appropriate for various datatypes, including continuous
real–valued, binary and count data.
• Collective Factorization: The challenge in effectively combining heterogeneous di-
vergences in a collective matrix factorization is that such divergences often span different
numerical scales and simple unweighted combinations tend to overfit datatypes or source
matrices whose divergences are in the higher numerical range. We propose an effective
heuristic approach to estimate appropriate weights for individual source matrices.
• Non–negativity and Sparsity: Physically interpretable latent factors are necessary to
extract clinically meaningful phenotypes from EHR data. Non–negative matrix factoriza-
tion (NMF) (Paatero and Tapper, 1994; Lee and Seung, 1999) in comparison to the more
traditional principal component analysis (PCA) provides better interpretability of the low–
rank factors as sum–of–parts representation. Such non–negativity constraints can be readily
extended into the CMF framework. Further, sparsity of latent factors representing the phe-
notypes plays a crucial role in the usefulness of the phenotypes as human experts need to
analyze the factors and conduct further investigation to validate its clinical relevance. Thus,
each phenotype should be ideally be represented by very few active components (≤ 10 non–
zero loading of entities) from each source. In one of the proposed variations of the generalize
collective NMF formulation, convex sparsity inducing constraints are introduced to enhance
the interpretability of extracted latent factors.
We empirically assess the proposed model on real EHR data from Vanderbilt University.
The clinical relevance of the extracted phenotypes are evaluated by domain experts.
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2. Related Work
In this paper, we address phenotype extraction from EHR data using unsupervised dimen-
sionality reduction techniques. Inferring low–dimensional representation of matrix data is
a fundamental problem in machine learning and a complete review of related techniques
is beyond the scope of the paper. We briefly discuss just the key models that are most
relevant to the work in this paper. PCA (Fodor, 2002; Jolliffe, 2002), the most popular and
widely used tool dimensionality reduction, learns latent factors as low rank matrices whose
values are unconstrained and can contain both positive and negative entries. However,
in many applications it is desirable to interpret the low rank factors as physical concepts
and negative entries often contradict physical reality. This motivated a related line of
dimensionality reduction techniques called the Non–Negative Matrix factorization (NMF)
(Paatero and Tapper, 1994; Lee and Seung, 1999). Several existing work extend matrix
factorization tools to analyze data from multiple matrices. Collective matrix factorization
(CMF) and its non–negative variants (Singh and Gordon, 2008) incorporate information
from multiple sources of matrix data using shared latent variables/factors. Alternatively,
regularized NMF variants have been proposed combining data from multiple sources Zhang
et al. (2011); Liu et al. (2013). The tools for matrix valued data have also been generalized
to higher order tensors, or multi–way arrays (see (Kolda and Bader, 2009) for a review).
Variants of non-negative tensor factorization (NTF) based on CANDECOMP–PARAFAC,
one of the most popular tensor decomposition models, and its applications to extract in-
terpretable latent/hidden factors have been proposed, e.g. Cichocki et al. (2009); Lee et al.
(2007); Cichocki et al. (2008); Acar et al. (2011); Yılmaz et al. (2011); Acar et al. (2014) and
references therein. However, most of these methods primarily utilize the least square loss
and may not be appropriate for all data types. We build on these existing work and propose
techniques for efficiently extracting structured latent factors from multiple sources of het-
erogeneous EHR data. The primary focus is on the interpretability of the low–dimensional
factors as meaningful phenotypes.
Although existing phenotyping methods rely on a labor–intensive supervision, unsuper-
vised models have been proposed to leverage the vast amount of EHR data for automatic
phenotype discovery. These models include the use of probabilistic graphical models to
cluster patient’s longitudinal trajectories (Schulam et al., 2015), deep learning to detect
characteristic patterns in clinical time series data (Che et al., 2015), and generative models
on static data (Chen et al., 2016). Yet these methods are not scalable and are ill-suited
for incorporating data from patients over a prolonged period of time (6+ months). Recent
work has illustrated the promise of NTF to generate phenotypes with minimal human su-
pervision using data over several years (Ho et al., 2014a,b; Wang et al., 2015; Henao et al.,
2015). However, as noted earlier, a tensor representation is not always available in EHR
data, at least not without introducing assumptions and potentially biasing the results.
3. Phenotyping from EHR Data
The notations used in the rest of the paper are summarized in Table 1. We assume that
the patient EHR data from V sources, such as medications, diagnosis, laboratory mea-
surements, etc. are available as matrix valued data whose rows correspond to a common
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Notation Description
[N ] Set of integers [N ] = {1, 2, . . . , N}
X(k) Column k of a matrix X ∈ Rnr×nc
Input
v=1, 2, . . . , V Index over V sources of EHR data, e.g. medication, diagnosis, etc.
np Number of patients
nv Number of entities in source type v
Xv ∈ Rnp×nv EHR data matrix from source v
X = [Xv]Vv=1 Collection of V EHR data matrices
Dv Bregman divergence appropriate for approximating Xv
Estimates
X̂ = [X̂v]Vv=1 Estimate of X from models
W ∈ Rnp×R Patients’ loading along the R dimensional latent space of interest
Hv ∈ Rnv×R Latent factor representation for features in source v
bv ∈ Rnv Bias factors associated with columns of the data matrix Xv
Table 1: Summary of Notations
set of patients, and columns represent entities from the respective sources (medications,
diagnosis, laboratory measurements, etc.). Let np denote the number of patients, and for
each source v ∈ {1, 2, . . . , V }, let nv denote the number of unique entities within the source
v. The collection of V matrices containing EHR data from multiple sources is denoted by
X = [Xv]Vv=1, where Xv ∈ Rnp×nv denotes the matrix data from source v.
3.1 Dataset Overview
We evaluate our models on an EHR data set from Vanderbilt University Medical Center.
This section contains a brief exploration of the data and the empirical results.
We used de-identified electronic medical records corresponding to the first ∼10,000 pa-
tients in BioVU1, the Vanderbilt DNA databank, spanning over 20 years. The details of
the inclusion and exclusion criteria for the databank are described in Ritchie et al. (2010).
For evaluation purposes, we focused on the case and control patients for type–2 diabetes
and resistant hypertension. These patients and their labels were selected by using the re-
spective rule–based phenotype algorithms defined in the Phenotype KnowledgeBase2. We
emphasize that labels from these rule-based algorithms were not used in our phenotyping
models which are learned in a completely unsupervised setting.
Although our model is general enough to be applied to multiple data types, we work
with counts of diagnoses and medications for evaluation purposes. The diagnosis codes, in
the form of International Classification of Disease, 9th edition (ICD-9) codes, were grouped
using the PheWAS code groups3, a custom-developed hierarchy which currently contains
1. https://victr.vanderbilt.edu/pub/biovu/
2. https://phekb.org
3. http://phewas.mc.vanderbilt.edu/
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∼ 1600 groups. Medications were aggregated based on Medical Subject Headings (MeSH)
pharmacological actions provided by the RxClass REST API, a product of the US National
Library of Medicine. Note that a medication may belong to multiple categories. Figure 1
provides example aggregations performed on the original table for the purpose of our study.
Finally, BioVU dataset assigns an index (reference) date to each patient, which corre-
sponds either to the date where the criteria was met (case patients) or the last encounter
date (control patients). The EHR records of patients falling in the date range of one year
prior to their index date up until the index date were used in our experiments. Any patient
without at least one diagnosis and medication during the relevant time period was not in-
cluded in our study. Our resulting data set contains 2039 patients, 936 diagnosis groups,
and 161 medication classes.
The dataset is summarized in Table 2 and the top five diagnosis and medication cate-
gories that appear in our data are shown in Table 3.
Pa#ent	   Date	   ICD-­‐9	  Code	   ICD-­‐9	  Descrip#on	  
1	   07/12/2009	   381.81	   Dysfunc2on	  of	  
Eustachian	  tube	  
1	   07/12/2009	   388.30	   TINNITUS	  NOS	  
1	   08/24/2009	   463	   Acute	  tonsilli2s	  
2	   09/07/2007	   724.1	   Pain	  in	  thoracic	  spine	  
2	   09/07/2007	   724.2	   Lumbago	  
ICD-9 Diagnosis Table 
Pa#ent	   Date	   Medica#on	  
3	   07/25/2012	   Fosamax	  
3	   07/25/2012	   Propranolol	  
3	   07/25/2012	   Tylenol	  
3	   08/15/2012	   Acetaminophen	  
3	   08/15/2012	   Docusate	  sodium	  
Medication Table 
Pa#ent	   Date	   PheWAS	   PheWAS	  Descrip#on	  
1	   07/12/2009	   381	   O22s	  media	  and	  Eustachian	  tube	  disorders	  
1	   07/12/2009	   388	   Other	  disorders	  of	  ear	  
1	   08/24/2009	   465	   Acute	  upper	  respiratory	  infec2ons	  of	  
mul2ple	  or	  unspecified	  sites	  
2	   09/07/2007	   724	   Other	  and	  unspecified	  disorders	  of	  back	  
2	   09/07/2007	   724	   Other	  and	  unspecified	  disorders	  of	  back	  
PheWAS Diagnosis Table 
Pa#ent	   Date	   Subclass	  
3	   07/25/2012	   Bone	  resorp2on	  inhibitors	  
3	   07/25/2012	   An2arrhythmic	  agents;	  Beta-­‐adrenergic	  blocking	  agents	  
3	   07/25/2012	   Analgesics	  
3	   08/15/2012	   Analgesics	  
3	   08/15/2012	   Laxa2ves	  
RxNorm Classes 
Figure 1: Examples of the aggregation from ICD-9 diagnosis codes to PheWAS code groups
and original medications to the MeSH pharmacological actions classes.
v Source Matrix Xv np × nv Datatype
1 Patient–Diagnosis 2039× 936 Count
2 Patient–Medication 2039× 161 Count
Table 2: Dataset summary.
Source Top five entities
Diagnosis Hypertension; Incision, excision, and division of other bones; Ischemic
Heart Disease; Secondary malignant neoplasm of respiratory and diges-
tive systems; Disorders of lipoid metabolism.
Medication Analgesics; Vitamins; Anticonvulsants; Anxiolytics, sedatives, and hyp-
notics; Antihyperlipidemic agents.
Table 3: The top five diagnosis and medications of the patients in our study.
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4. Structured Collective Matrix Factorization for Phenotyping
For each source v ∈ [V ], we approximate Xv by structured estimates X̂v which incorporates
model constraints appropriate for effective phenotyping.
4.1 Heterogeneous Datatypes
In EHR data from multiple sources, each source matrix Xv may contain data represented in
diverse datatypes (e.g., binary values for demographics, count values for medications, or con-
tinuous values for laboratory measurements). In our phenotyping models, the data fidelity
of X̂v is quantified using an appropriately chosen source–specific divergence Dv(Xv, X̂v).
The divergence functions are selected from a class of Bregman divergence defined as follows:
Definition 1 (Bregman Divergence) Let φ be a strictly convex function differentiable
in the relative interior of dom(φ). The Bregman divergence (associated with φ) between
x ∈ dom(φ) and y ∈ ri(dom(φ)) is defined as:
Dφ(x, y) = φ(x)− φ(y)− 〈∇φ(y), x− y〉.
The motivation for using Bregman divergences are two fold. Bregman divergences include
rich classes of loss functions that are appropriate for a variety of datatypes including
(weighted) squared loss for continuous valued data, logistic loss for binary valued data,
and generalized KL divergence for count valued data among others (Banerjee et al., 2005).
These loss functions are also equivalent to the negative log–likelihood of members of ex-
ponential family distributions including Gaussian, Bernoulli, Poisson, exponential among
others (Banerjee et al., 2005). Thus, the domain knowledge of data distribution can be
potentially incorporated in choosing the appropriate divergence. Secondly, Bregman di-
vergences are strictly convex and differentiable in the first parameter, and accurate and
tractable estimators for X̂v can be developed using gradient descent and alternating mini-
mization algorithms.
In our dataset described in Section 3.1, as both the matrices described in Section 3.1
have count valued data we use the generalized KL divergence given by the following equation
as the divergence for both sources:
D(X, X̂) =
∑
ij
X̂ij −Xij +Xij log Xij
X̂ij
. (1)
4.2 Generalized Collective NMF (CNMF)
As noted earlier, non–negativity constraints on the patient loading and latent factor matrices
allow for better interpretability as sum–of–parts representation. We propose a generalized
collective NMF (CNMF) as a basic model for extracting phenotypes from multiple sources
of patient data available in heterogeneous datatypes. In Section 4.3, we introduce additional
structures to enhance interpretability.
Each source of EHR data v is associated with a structured latent factor matrix Hv ∈
Rnv×R, and these factors jointly span a shared latent space. The columns of Hv concate-
nated across the V sources are potential candidates for phenotypes. The loading of the
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patients along these latent dimensions are given by the matrix W ∈ Rnp×R. Addition-
ally, the raw EHR data often contains generic features that are not necessarily indicative
of any medical condition of interest. For example, medications like pain reliever, labora-
tory measurements like body temperature, etc. are frequently encountered in patient data,
but are not discriminative of patient conditions. EHR data from such frequent and non–
discriminative features are captured through an explicit (and potentially dense) column or
feature bias factor bv ∈ Rnv for each source v.
For v ∈ [V ], the source matrix Xv is approximated as WH>v + 1b>v , where 1 is a vector
of all ones in appropriate dimensions. We use a Bergman divergence Dv appropriate for
each source to measure the data fidelity of the estimate to the observed data. Finally, as the
heterogeneous divergences are in different scales, we weight the divergence corresponding
to each source using weight parameter αv, v = 1, 2, . . . , V . The basic CNMF estimator is
given by the following optimization problem.
X̂ = argmin
{X̂v}v∈[V ]
V∑
v=1
αvDv(Xv, X̂v),
s.t. X̂v = WH
>
v + 1b
>
v for v=1, 2, . . . , V,
W ∈ Rnp×R+ , Hv ∈ Rnv×R+ , bv ∈ Rnv+ .
(2)
4.2.1 Computing {αv : v = 1, 2, . . . , V }
As noted earlier, since the divergences associated with difference datatypes span different
numerical scales, unweighted objective in (2) will tend to overfit the matrices whose diver-
gences are in the higher numerical range. We propose an effective heuristic approach to
estimate contribution of each source matrix Xv in the joint estimation. To motivate the
idea, consider a source matrix Xv. If a joint factorization is not required, i.e. W need
not be shared, then the optimization problem in (2) can be solved as V independent struc-
tured factorization X˜ indv = WvH
>
v + 1b
>
v without the weights αv. In a preprocessing step,
for each source and independent factorization of the form X˜ indv is learned by minimizing
Dv(Xv, X˜
ind
v ) assuming the sources to be independent of each other. The resultant diver-
gence from independent factorization is treated as the effective scale of divergence for each
source. To assign equal importance to all source matrices, we choose ∀v, αv = 1
Dv(Xv ,X˜indv )
.
4.3 Sparsity–inducing CNMF (SiCNMF)
As phenotypes learned form data analysis tools are further investigated by human experts,
it is desirable that candidate phenotypes learned from EHRs are sparse combinations of the
source entities, i.e., columns Hv are sparse.
To illustrate our sparsity–inducing constraints for enhanced interpretability, we first con-
sider a single source of EHR data matrix X ∈ Rnp×n and an appropriate divergence function
D(.). Explicit sparsity constraints on the factor matrix H lead to intractable combinatorial
optimization problems. A commonly used convex surrogate for sparsity involves restricting
the `1 norm of the columns of H, i.e., constraints of the form {‖H(k)‖1 ≤ s : k ∈ [R]},
for some parameter s. However, in (2) if the scaling of W is unrestricted, then due to
multiplicative nature of the factorization, restrictions on norm of H tend to be ineffective
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as any scaling of H can be easily absorbed by W . Thus, we additionally constrain the scale
of W using a Frobenius norm constraint of the form ‖W‖F ≤ η, for another parameter η.
We note that, s and η effectively work as single parameter due to the multiplicative update.
Thus, without loss of generality, we fix s = 1 and use η as a tunable parameter to control
the sparsity level.
We propose the following generalized SiCNMF model as an extension of vanilla CMF
which incorporates (a) sparsity–inducing and non–negativity constraints for enhanced in-
terpretability, (b) feature specific bias factors {bv : v ∈ [V ]} to capture data specific offsets,
and (c) appropriately weighted heterogeneous divergences to handle varied datatypes.
X̂ = argmin
{X̂v}v∈[V ]
V∑
v=1
αvDv(Xv, X̂v),
s.t. X̂v = WH
>
v + 1b
>
v for v=1, 2, . . . , V,
W ∈ Rnp×R+ , Hv ∈ Rnv×R+ , bv ∈ Rnv+ ,
‖W‖F ≤ η, ‖H(k)v ‖1 = 1 ∀k ∈ [R],
(3)
where recall that H
(k)
v is the kth column of Hv, and αv are either (a) all ones (unweighted
SiCNMF), or (b) computed using the methodology described in Section 4.2.1 (weighted
SiCNMF). Note that the higher the value of η, the weaker the sparsity constraint. In the
limiting case of η =∞, the model is equivalent to the heterogeneous collective non–negative
matrix factorization (CNMF) as scaling constraints of Hv are captured by W .
5. SiCNMF: Algorithm Details
For any set of Bregman divergences {Dv : v = 1, 2, . . . V } and positive parameters η, {αv} >
0 , the optimization problem (3) is convex in [(Hv, bv) ∀v] when W is fixed and vice versa.
Our algorithm uses alternating minimization to solve (3) where each iteration alternatively
minimizes [(Hv, bv) ∀v] and W , while keeping the other fixed. Each such component update
involves minimizing a smooth convex objective subject to convex constraint set and is solved
using projected gradient decent algorithm with backtracking line search to determine step
size (Lin, 2007).
Recent work has shown that projected gradient methods are computationally com-
petitive and have better convergence properties than standard multiplicative update ap-
proaches (Lin, 2007). Moreover, compared to multiplicative updates, projected gradient
descent based algorithms can be easily extended for convex constraints beyond simple non–
negativity. Although Lin (2007) ignore the KL divergence problem as ill-defined, a more
recent work (Chi and Kolda, 2012) provide convergence for related tensor factorization task
by showing that the convex hull of the level sets of the KL divergence problem is compact.
To project onto the simplex, we used the simple and fast algorithm proposed by Chen and
Ye (Chen and Ye, 2011).
Our algorithm to solve (3) is described in Algorithm 1.
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Algorithm 1: Alternating minimization for (3) using projected gradient descent
Input : EHR data Xv, Dv(.) for v = 1, 2, . . . , V
Parameters : Divergence weights {αv} and tunable sparsity inducing parameter
η ∈ (0,∞)
Output: Patient loadings Ŵ , factors/phenotypes {Ĥv} and feature biases {b̂v}
while not converged do
Ŵ =
argmin
W≥0
V∑
v=1
αvDv(Xv,WĤ
>
v + 1b̂
>
v )
s.t. |W‖F ≤ η, W ≥ 0.
for v ∈ [V ] do
Ĥv, b̂v =
argmin
Hv≥0,bv≥0
Dv(Xv, ŴH
>
v + 1b
>
v )
s.t. ∀k, ‖H(k)v ‖1 = 1.
end
end
6. Experiments
The generalized KL–divergence (1) is used as loss function for both matrices (patient by
diagnosis and patient by medication) in the collective matrix factorization models as well
as the baselines described in the following subsection.
6.1 Baseline Models
The primary focus of the paper is the clinical relevance of candidate phenotypes obtained
from unsupervised dimensionality reduction techniques. Since the Vanderbilt data contains
flat files associated with the diagnosis codes and medications, construction of the patient–
medication and patient–diagnosis matrices for the collective matrix factorization models
were straightforward. Our models of CNMF (2) and SiCNMF (3) are compared with two
baseline models described below:
• Non–negative matrix factorization (NMF) (Lee and Seung, 1999): In or-
der to evaluate traditional NMF in identifying a shared latent space, we aggregate
the patient information into a third matrix, diagnosis by medication, wherein each
element represents the number of patients who have at least one occurrence of both
the diagnosis and the medication during our one year time window. It is important
to note that under this construction, a patient with two encounters almost one year
apart, one with the diagnosis A and one with medication B would be counted in the
(A,B)th entry of the matrix. A non–negative matrix factorization model with the
generalized KL divergence as the objective and no sparsity constraints is performed
on the diagnosis by medication matrix.
• Marble (Ho et al., 2014b): Marble is a sparse non–negative tensor factorization
model that has been used to obtain highly effective and interpretable phenotypes
provided a multiway tensor EHR data is available. However, our dataset does not
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have rich multi–way interactions to easily construct tensors. For example, in a patient–
diagnosis–medication tensor, a entry xijk denotes the number of times a patient i was
prescribed medication k in order to treat a diagnosis j. To construct tensors from
available flat files, we approximate these interactions by assuming that a medication
was used to treat a specific diagnosis if both diagnosis and medication occur within
a one week time interval, that is the counter for xijk is incremented if patient i was
prescribed medication k within one week of an encounter with diagnosis j. Marble
applied to this approximated tensor is our second baseline.
The baselines described above are compared to three CMF based models described in
this paper: (a) CNMF (2) which does not incorporate the sparsity inducing constraints,
(b) unweighted SiCNMF which incorporates sparsity–inducing constraints proposed in Sec-
tion 4.3, but uses a simple aggregation of various source divergences, i.e., solves (3) with
αv = 1 for all v ∈ [V ], and finally (c) weighted SiCNMF which incorporates both the
sparsity–inducing structure and the weights αv computed using the heuristic described in
Section 4.2.1.
All the models described above involve non–convex optimization and the estimates from
the algorithm are sensitive to initialization. To mitigate this issue from local minima, we run
each algorithm independently multiple times and pick the run with best fit to the objective.
All the competing models learn a R = 20 rank factorization.
6.2 Sparsity–accuracy trade off: Data fit
The sparsity of the candidate phenotypes plays a crucial role in the interpretability and
wider applicability of the estimates. Concise representations allow domain experts to more
easily reason about a particular group of patients queried using the phenotypes. As noted
earlier, while non–negativity constraint in matrix and tensor factorization inherently induce
sparsity as a by–product, there is no explicit control over the sparsity levels. Thus in
order to deriving extremely sparse phenotypes involve, we introduce a sparsity inducing
regularization, whose sparsity levels can be controlled by an tunable knob of η in (3).
The expected sparsity–accuracy trade-off in the data fit can be observed in Figure 2.
Note that higher values of η in (3) correspond to a weaker sparsity constraints as the W
factor can more easily absorb the scaling constraint on Hv.
6.3 Type-2 diabetes and Resistant hypertension prediction
With relaxed sparsity constraints, while a monotonic decay of objective function on training
data fit as observed in Figure 2 is expected, such a monotonic accuracy trade-off does extend
for predictions on held out test datasets. Besides improving interpretability, the sparsity
constraints further function as regularization to prevent overfitting.
To quantitatively evaluate the effectiveness of the extracted phenotypes, we consider
the classification problem of predicting two chronic conditions prevalent in the patient
population of our dataset (Section 3.1): (a) type-2 diabetes, and (b) resistant hypertension.
As described in Section 3.1, for each patient in our dataset, the class labels for these chronic
conditions were estimated from rule-based phenotyping algorithm from PheKb.
Our full dataset of ∼ 2000 patients is divided into 5 stratified cross validation folds of
80% training and 20% test patients. For each cross-validation fold, the models described
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Figure 2: Sparsity–accuracy trade-off in data fit of weighted SiCNMF. Sparsity is measured
as the median number of non-zero entries in columns of the phenotype matrices concatenated
from all sources {Ĥv : v = 1, 2, . . . , V }. (a) Each box plot represents the spread of the
number of non–zeros in R = 20 candidate phenotypes learned from weighted SiCNMF
using η represented along the x–axis in (3). (b) Plot of decay of divergence between the
fitted estimate and the observed data as the sparsity constraint is relaxed using higher η.
Note that the values of η along x–axis are not in linear scale and higher values correspond
to weaker sparsity–inducing regularization.
in Section 6.1 were applied on training EHR dataset to extract the phenotype matrices
{Ĥtrainv : v ∈ [V ]}. We clarify that, for all the competing models, the phenotypes (latent
factors) were extracted (a) only from EHR data of patients in the training set, and (b) the
estimates were learned in a completely unsupervised setting. In particular, the test EHR
data and the labels were not used in the phenotype extraction phase.
For each patient, the R dimensional loading along the phenotype/latent space spanned
by {Ĥtrainv : v ∈ [V ]} is used as features for learning the classifiers. Such representa-
tions are computed by projecting the EHR matrix into the fixed phenotype factors. For
CMF variants, the features for a patient with EHR [Xpatientv ] is given by: W patient =
argmin
W≥0
∑
v αvDv(X
patient
v ,WHtrainv + 1b
train>
v ).
The sparsity–accuracy trade-off in prediction performance on held out dataset is plot-
ted in Figure 3. Although, the predictive performance at various η levels are statistically
comparable, the mild regularization effect of sparsity constraints can be observed the plots.
6.4 Sparsity and Prediction Comparison to Baseline Models
So far in the experiments, we have mainly focused on the effect of sparsity parameter on
data fit and prediction performance. In this subsection, we compare the performance CMF
based estimators to strong baselines models.
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Figure 3: Sparsity–accuracy tradeoff in prediction of (a) Type–2 diabetes and (b) resistant
hypertension. The results are for weighted SiCNMF, but similar tradeoff was also observed
for unweighted SiCNMF. Note that x–axis is not linear and higher η leads to lower sparsity
(more number of non-zeros in phenotype representations)
6.4.1 Sparsity
The sparsity patterns obtained by the competing phenotyping algorithms described in Sec-
tion 6.1 are compared in Figure 4. As expected, the sparsity of SiCNMF models are better
than those of non–sparsity–inducing CNMF and NMF models. NMF (Lee and Seung,
1999) on dense aggregated data which does not incorporate explicit sparsity constraints
learns dense factor matrices. We note that CNMF models multiple sparse matrices jointly
learns much sparser factors compared to NMF on single aggregated matrix. Marble (Ho
et al., 2014b) induces sparsity by truncation and achieves the best sparsity performance.
6.4.2 Prediction
The classification performance of baseline models for predicting type-2 diabetes and resis-
tant hypertension are compared in Figure 5. We note here that as NMF uses aggregated
data of patients and there is no easy approach to learn individual patient representations
in the phenotype space. Thus, we exclude NMF from this set of experiments. Instead we
use the classifiers learned on full concatenated EHR matrix as an additional baseline for
prediction performance. Note that the concatenated EHR matrix has > 1000 features com-
pared to the 20 dimensional representation of the rest of the models. It is observed that the
phenotype based models with 20 dimensional feature representation have comparable per-
formance. However, the classifiers from full EHR matrix with > 1000 features outperforms
the phenotype–based models. While the EHR matrix provides a richer set of features for
prediction performance, the high dimensional EHR data are not not useful for phenotyping
applications and interpretability.
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Figure 4: Box plots showing the inherent sparsity induced by the models.
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Figure 5: Accuracysparsity tradeoff in prediction
6.5 Clinical Relevance of Phenotypes
The phenotypes extracted from the models described above are evaluated by a human expert
for clinical relevance. For reasonable evaluation of the phenotypes by humans, it is desirable
that each phenotype be represented by a very small number of diagnoses and medications
groups. Based on a round of feedback from our clinical experts, in post processing, we
retain just the top 5 medications and top 5 diagnosis from phenotypes learned from all the
models for evaluation in this section.
We evaluated the clinical relevance of the resulting phenotypes from the phenotyping
models by conducting a survey with a domain expert. The domain expert was given 20
phenotypes from each model to assess and were not informed apriori the correspondence
between the models and the results. For each of the individual phenotypes, the experts
assigned one of three values: (1) yes – it was clinically meaningful, (2) possible
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– the phenotype has some clinical meaningfulness, and (3) no – it was not
meaningful at all.
The annotated results for the models are compared in Figure 6. The results show
that weighted CMF based algorithms perform significantly better in producing potentially
clinical meaningful groupings. In an earlier work, Ho et. al. Ho et al. (2014b) show that for
tensor valued data, Marble is very effective for phenotyping. The improved performance of
CMF based algorithms compared to Marble signifies the shortcomings of approximating the
tensor from flat files, besides the additional computational cost of factorizing higher order
tensors. Moreover, the improved performance of weighted SiCNMF compared to unweighted
SiCNMF corroborates the efficacy of the weighing scheme described in Section 4.2.1.
NMF Marble SiCNMF
(unweighted)
SiCNMF
(weighted)
CNMF
0
5
10
15
20
Yes Possible No
Figure 6: The distribution of the clinical relevance scores across the various models.
We note that although we could have performed SiCNMF on data that contains only
the case patients to potentially yield more clinically relevant phenotypes, the purpose of our
experiment was to demonstrate the unsupervised nature of our algorithm on a heterogeneous
patient population.
Finally, Tables 4 and 5 show examples of phenotypes derived from weighted SiCNMF
and CNMF, that were rated to be clinically meaningful by the domain experts.
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Diagnosis Medication
ischemic heart disease; hypertension; disorders
of lipoid metabolism; late effects of cerebrovas-
cular disease; occlusion of cerebral arteries;
antihyperlipidemic agents;
cholinesterase inhibitors; antiangi-
nal agents; analgesics; antiplatelet
agents;
chronic airway obstruction, not elsewhere clas-
sified; other diseases of lung; dyspnea and respi-
ratory abnormalities; pneumonia, organism un-
specified; hypertension;
bronchodilators; antiarrhythmic
agents; calcium channel blocking
agents; antiviral agents; medical
gas;
malignant neoplasm of colon; rheumatoid arthri-
tis and other inflammatory polyarthropathies;
malignant neoplasm of rectum, rectosigmoid
junction, and anus; secondary malignant neo-
plasm of respiratory and digestive systems; dis-
orders involving the immune mechanism;
immunosuppressive agents; an-
tirheumatics; antimetabolites;
antipsoriatics; adrenal cortical
steroid;
Table 4: Phenotypes from weighted–SiCNMF (η = 500) that were evaluated as “clinically
meaningful” by our domain expert.
Diagnosis Medication
ischemic heart disease; hypertension; disorders
of lipoid metabolism; unspecified chest pain;
myocardial infarction;
antianginal agents; antihyperlipi-
demic agents; vasodilators; an-
tiplatelet agents; angiotensin con-
verting enzyme inhibitors
heart failure; atrial fibrillation and flutter; hy-
pertension; pulmonary heart disease; dyspnea
and respiratory abnormalities;
diuretics; antiarrhythmic agents;
calcium channel blocking agents
bronchodilators;aldosterone recep-
tor antagonists;
malignant neoplasm of colon; rheumatoid arthri-
tis and other inflammatory polyarthropathies;
regional enteritis; malignant neoplasm of rec-
tum, rectosigmoid junction, and anus; ulcerative
colitis;
immunosuppressive agents; an-
tirheumatics; analgesics; vitamins;
antimetabolites;
chronic kidney disease (CKD); diabetes melli-
tus, type 2 Complications peculiar to certain
specified procedures; other and unspecified ane-
mias; diabetes mellitus, Type 1;
antidiabetic agents; miscellaneous
antibiotics; sulfonamides; recombi-
nant human erythropoietins; glu-
cose elevating agents;
Table 5: Phenotypes from CNMF (no sparsity constraints) that were evaluated as clinically
meaningful by our domain expert.
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7. Conclusions
Unsupervised learning approaches for automated phenotyping have the potential to enable
improved clinical trials, properly target patients for screening tests and interventions, and
support surveillance of infectious diseases. However, traditional dimensionality reduction
tools are not immediately well–suited for the phenotype extraction process. In this pa-
per, we have introduced an unsupervised, structured collective matrix factorization tool
that incorporates various application specific constraints into a joint low rank factorization
framework. This framework is used for phenotype extraction from multi–source EHR data
from Vanderbilt University. The clinical relevance of extracted candidate phenotypes were
evaluated by a domain expert and the results show improved performance over existing
baseline models.
We intend to extend our studies along several directions. EHR data is often subject to
noise and missing data. As a first extension of this work, we plan to quantitatively study the
robustness of the extracted phenotypes to (a) missing data, (b) noise in data, and (c) varying
patient populations. Preliminary results in this direction are very encouraging. Secondly, in
the current framework, we post–process the candidate phenotypes to enforce hard sparsity
requirements. We would like to explore models and algorithms that implicitly incorporate
such sparsity constraints, potentially along the lines of the sparse simplex projection by
Kyrillidis et al. (2012).
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